Alethio Therapeutics
Alethio Therapeutics is an Oxford biopharmaceutical company developing therapies for myeloproliferative neoplasms. It raised $90 million in Series A funding.
- Industry
- biotech
- Location
- Oxford, United Kingdom
- Website
- https://alethiotherapeutics.com
About
Alethio Therapeutics is a biopharmaceutical company developing therapies for myeloproliferative neoplasms (MPNs). Its lead programme is ATX-011. The company release is datelined Oxford, United Kingdom, and the issue calls the company Oxford-based, so this page stores Oxford. BioPharma Dive calls it headquartered in Abingdon, Oxfordshire, and the company site footer lists an Abingdon Science Park address. Abingdon is not stored as the city. The company site is https://alethiotherapeutics.com.
The company release is dated 5 November 2026, so the round date is 2026-11-05. The release, BioPharma Dive, the Oxford RDM note, European Biotechnology and the issue agree on a $90 million Series A. $90,000,000 is stored. The release also states £67 million. The release says the funds will advance ATX-011 through Phase 1/2a studies in essential thrombocythaemia up to Phase 3 readiness, and additional MPN programmes toward IND submission.
Sofinnova Partners and RA Capital Management co-led. The issue writes RA Capital, and the round links to the existing RA Capital Management page. Oxford Science Enterprises, Cancer Research Horizons and the University of Oxford participated. The founders, Adam Mead and Beth Psaila, and CEO Rohit Batta do not have pages.
Funding history
| Round | Date | Amount | Lead |
|---|---|---|---|
| Series A 2026 | 2026-11-05 | $90M | Sofinnova Partners, RA Capital Management |
Investors
- Sofinnova Partners lead
- RA Capital Management lead
- Oxford Science Enterprises participant
- Cancer Research Horizons participant
- University of Oxford participant
Sources
Last verified:
- https://alethiotherapeutics.com/alethio-therapeutics-raises-90-million-67-million-in-oversubscribed-series-a-financing-to-advance-a-new-generation-of-therapies-for-myeloproliferative-neoplasms/
Type: company announcement. Accessed 2026-11-05.
Alethio Therapeutics release, datelined Oxford, United Kingdom, 5 November 2026. Says oversubscribed $90 million (£67 million) Series A co-led by Sofinnova Partners and RA Capital, alongside founding investor Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford. Says proceeds will advance ATX-011 through Phase 1/2a studies in essential thrombocythaemia up to Phase 3 readiness, and additional MPN programmes toward IND submission. Says the company is a University of Oxford spin-out founded by Professors Adam Mead and Beth Psaila. Footer contact address lists Sovereign House, Abingdon Science Park. - https://www.biopharmadive.com/news/alethio-therapeutics-myeloproliferative-neoplasms-series-a/873775/
Type: reputable publication. Accessed 2026-11-05.
BioPharma Dive. Says Alethio Therapeutics announced Nov. 5, 2026 it raised $90 million in Series A financing co-led by Sofinnova Partners and RA Capital Management, backed by Cancer Research Horizons, Oxford Science Enterprises and the University of Oxford. Calls the company headquartered in Abingdon in Oxfordshire, England. - https://www.rdm.ox.ac.uk/news/alethio-spin-out-series-a
Type: reputable publication. Accessed 2026-11-05.
University of Oxford Radcliffe Department of Medicine news. Says Alethio Therapeutics secured $90 million (£67 million) in oversubscribed Series A financing co-led by Sofinnova Partners and RA Capital, alongside Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford. - https://european-biotechnology.com/latest-news/oxford-spinout-alethio-raises-90m-series-a-for-chronic-blood-cancer-trials/
Type: reputable publication. Accessed 2026-11-05.
European Biotechnology Magazine. Says University of Oxford spinout Alethio Therapeutics raised $90 million Series A co-led by Sofinnova Partners and RA Capital, alongside Oxford Science Enterprises, with support from Cancer Research Horizons and the University of Oxford. - https://buttondown.com/raisetrack/archive/raise-track-update-2026-11-05/
Type: other verified public source. Accessed 2026-11-05.
Raise Track Update for 2026-11-05, Section 1. Amount line $90M (Series A). Calls Alethio an Oxford, UK-based biopharmaceutical company. Names Sofinnova Partners, RA Capital, Oxford Science Enterprises, Cancer Research Horizons, and University of Oxford.